Wave Life Sciences Ltd. 8-K

What Happened
Wave Life Sciences Ltd. (referred to as “Wave-Singapore”) announced on April 21, 2026 that a hearing has been set related to its proposed redomiciliation of the parent company from Singapore to a Delaware corporation (referred to as “Wave-Delaware”). The company attached a press release dated April 21, 2026 as Exhibit 99.1 to the Form 8-K and said it expects to file a definitive proxy statement with the SEC about the Redomiciliation and other related materials.

Key Details

• Press release titled “Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States” filed April 21, 2026 (Exhibit 99.1).
• Wave-Singapore expects to file and mail a definitive proxy statement to shareholders regarding the Redomiciliation; a preliminary proxy was filed April 15, 2026.
• Wave-Singapore and certain executive officers and directors may be participants in the proxy solicitation; prior director/officer holdings are described in Wave’s proxy for the 2025 Annual Meeting (filed June 23, 2025).
• The filing includes a caution that the Redomiciliation is subject to shareholder and Singapore Court approvals and other closing conditions and discloses forward‑looking risks (timing, costs, regulatory/tax changes, etc.).

Why It Matters
Redomiciliation would change the parent company’s jurisdiction from Singapore to Delaware, which could affect corporate governance, regulatory filings and tax considerations. Investors should read the definitive proxy statement and related SEC filings (when available) before voting or making investment decisions, since completion depends on shareholder and court approvals and other conditions described in the filing.